Themis Medicare Limited Share Price

Equities

THEMISMED

INE083B01024

Pharmaceuticals

Market Closed - Bombay S.E. 03:30:50 26/04/2024 pm IST 5-day change 1st Jan Change
216.3 INR +2.78% Intraday chart for Themis Medicare Limited +3.67% +1.60%
Sales 2022 3.95B 47.33M Sales 2023 3.54B 42.5M Capitalization 10.73B 129M
Net income 2022 729M 8.74M Net income 2023 569M 6.82M EV / Sales 2022 2.33 x
Net Debt 2022 595M 7.13M Net Debt 2023 798M 9.58M EV / Sales 2023 3.25 x
P/E ratio 2022
11.8 x
P/E ratio 2023
18.9 x
Employees 996
Yield 2022
0.54%
Yield 2023
0.43%
Free-Float 21.11%
More Fundamentals * Assessed data
Dynamic Chart
Themis Medicare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Themis Medicare Limited Launches REMITHEM CI
Themis Medicare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Themis Medicare Limited Announces Incorporation of Wholly Owned Subsidiary CI
Themis Medicare Limited Announces Cessation of Vijay Agarwal as Independent Director CI
Themis Medicare Limited Appoints Reena Patel as Alternate Non-Executive Non- Non-Independent Director to Dr. Adam Demeter, Effective September 11, 2023 CI
Themis Medicare Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Themis Medicare Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Themis Medicare Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Themis Medicare Limited Recommends Dividend for Financial Year Ended 31 March 2023 CI
Themis Medicare Limited Announces Board Resignations CI
Themis Medicare Gets Drug Controller General of India’s No-Objection for Diclofenac Injection MT
Themis Medicare Announces DCGI Approval of Remifentanil Hydrochloride 1mg/2mg for Injection for Import and Marketing CI
Themis Medicare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Themis Medicare Launches Drug for Treatment of Menopausal Symptoms in India MT
More news
1 day+2.78%
1 week+3.67%
Current month-1.23%
1 month-3.13%
3 months-4.59%
6 months+40.41%
Current year+1.60%
More quotes
1 week
205.80
Extreme 205.8
218.30
1 month
203.30
Extreme 203.3
235.70
Current year
192.75
Extreme 192.75
266.00
1 year
131.34
Extreme 131.34
266.00
3 years
34.61
Extreme 34.61
266.00
5 years
13.99
Extreme 13.99
266.00
10 years
6.11
Extreme 6.105
266.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 29/04/29
Director of Finance/CFO - 01/16/01
Chairman 75 01/73/01
Members of the board TitleAgeSince
Chief Executive Officer 49 29/04/29
Chairman 75 01/73/01
Director/Board Member 70 01/77/01
More insiders
Date Price Change Volume
26/24/26 216.3 +2.78% 3,972
25/24/25 210.4 +0.26% 7,178
24/24/24 209.9 -1.52% 10,303
23/24/23 213.2 +2.77% 4,375
22/24/22 207.4 -0.60% 1,908

Delayed Quote Bombay S.E., April 26, 2024 at 03:30 pm IST

More quotes
Themis Medicare Limited is an India-based company, which is engaged in the manufacturing of pharmaceutical products, especially in formulation and active pharmaceutical ingredients (API) activity. The Company operates through one segment: Pharmaceuticals. The Company manufactures therapeutic pharma products, differential healthcare products, and APIs based in India. Its analgesic and anti-inflammatory products include Aquadol Tpm Gel, Etojet 90 10'S, Etojet 120 10'S, Etojet Mr Tablets 10'S, Etojet XP Gel, Themidol-P Tab 10's, Dhoom, Aquadol inj, Dyloaqua inj, Joydol -P, Joydol -SP, Joydol -TH, and Nimujet Gel. Its Analgesics products include Anemol, Tazowin, Themidol, Themidol. Its Anesthesia products include Bupicaine 0.25%, Ketmin 2 Vial, Ketmin 5, Ropicaine 2, Themicaine 2%, and more. Its subsidiaries include Artemis Biotech Limited, Themis Lifestyle Private Limited, and Carpo Medical Limited (UK).
More about the company
  1. Stock Market
  2. Equities
  3. THEMISMED Stock